Companies Indivior PLC FollowJune 2 (Reuters) - Indivior Plc (INDV.L) said on Friday it agreed to pay $102.5 million to settle a lawsuit by dozens of U.S. states accusing it of illegally suppressing generic competition for its opioid addiction treatment Suboxone.
Suboxone was approved for U.S. sale in 2002, and Indivior had the exclusive right to sell the treatment in tablet form until 2009.
States said Indivior switched to an oral film version of Suboxone from a tablet version to extend its monopoly, just as generic manufacturers were poised to sell their own lower-cost tablets.
Generic tablets obtained federal approval in 2013.
Indivior expects to pay the $102.5 million in cash this month.
Persons:
drugmaker, Indivior, Suboxone, Josh Kaul, Mariam Sunny, Jonathan Stempel, Maju Samuel, Matthew Lewis
Organizations:
Indivior, D.C, U.S, U.S . Centers for Disease Control, Thomson
Locations:
Chesterfield , Virginia, U.S, Washington, Indivior's, Philadelphia, Suboxone, Wisconsin, United States, Bengaluru, New York